Unknown

Dataset Information

0

Rapamycin rescues ABT-737 efficacy in small cell lung cancer.


ABSTRACT: Overexpression of the antiapoptotic protein Bcl-2 is observed in the majority of small cell lung cancer (SCLC) cases and is associated with resistance to chemotherapy. While targeting Bcl-2 in hematologic malignancies continues to show signs of promise, translating the BH3 mimetic ABT-737 (or ABT-263; navitoclax) to the clinic for solid tumors has remained problematic, with limited single-agent activity in early-phase clinical trials. Here, we used patient-derived xenograft (PDX) models of SCLC to study ABT-737 resistance and demonstrated that responses to ABT-737 are short lived and coincide with decreases in HIF-1?-regulated transcripts. Combining the mTOR inhibitor rapamycin with ABT-737 rescued this resistance mechanism, was highly synergistic in vitro, and provided durable tumor regressions in vivo without notable hematologic suppression. In comparison, tumor regressions did not occur when ABT-737 was combined with etoposide, a gold-standard cytotoxic for SCLC therapy. Rapamycin exposure was consistently associated with an increase in the proapoptotic protein BAX, whereas ABT-737 caused dose-dependent decreases in BAX. As ABT-737 triggers programmed cell death in a BAX/BAK-dependent manner, we provide preclinical evidence that the efficacy of ABT-737 as a single agent is self-limiting in SCLC, but the addition of rapamycin can maintain or increase levels of BAX protein and markedly enhance the anticancer efficacy of ABT-737. These data have direct translational implications for SCLC clinical trials.

SUBMITTER: Gardner EE 

PROVIDER: S-EPMC4510983 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rapamycin rescues ABT-737 efficacy in small cell lung cancer.

Gardner Eric E EE   Connis Nick N   Poirier John T JT   Cope Leslie L   Dobromilskaya Irina I   Gallia Gary L GL   Rudin Charles M CM   Hann Christine L CL  

Cancer research 20140310 10


Overexpression of the antiapoptotic protein Bcl-2 is observed in the majority of small cell lung cancer (SCLC) cases and is associated with resistance to chemotherapy. While targeting Bcl-2 in hematologic malignancies continues to show signs of promise, translating the BH3 mimetic ABT-737 (or ABT-263; navitoclax) to the clinic for solid tumors has remained problematic, with limited single-agent activity in early-phase clinical trials. Here, we used patient-derived xenograft (PDX) models of SCLC  ...[more]

Similar Datasets

| S-EPMC3159963 | biostudies-literature
| S-EPMC5358954 | biostudies-literature
| S-EPMC3944277 | biostudies-literature
| S-EPMC3459262 | biostudies-literature
| S-EPMC8688371 | biostudies-literature
| S-EPMC6204323 | biostudies-literature
| S-EPMC2921023 | biostudies-literature
| S-EPMC9806293 | biostudies-literature
| S-EPMC4847809 | biostudies-literature
| S-EPMC3527691 | biostudies-literature